UPDATE: Pain Therapeutics (PTIE), DURECT (DRRX) Sink in Active Trade
Tweet
Share
E-mailGet Alerts PTIE Hot Sheet
Join SI Premium – FREE
(Updated - November 1, 2012 11:13 AM EDT)
Both Pain Therapeutics Inc. (Nasdaq: PTIE) and DURECT Corporation (Nasdaq: DRRX) are under heavy pressure Thursday, raising eyebrows among traders. Pfizer had its conference call today and traders would have been looking for commentary on Remoxy. It is unclear at this point what, if anything Pfizer said.
PTIE is down 23 percent and DRRX is down 38 percent, having been halted numerous times.
UPDATE: It is now being said among biotech watchers that Pfizer noted "problems" lingering with FDA on the re-file.
From @adamfeuerstein on twitter:
RT @JNapodano: @adamfeuerstein Yes, apparently $PFE noted "problems" lingering with FDA on the re-file.
Both Pain Therapeutics Inc. (Nasdaq: PTIE) and DURECT Corporation (Nasdaq: DRRX) are under heavy pressure Thursday, raising eyebrows among traders. Pfizer had its conference call today and traders would have been looking for commentary on Remoxy. It is unclear at this point what, if anything Pfizer said.
PTIE is down 23 percent and DRRX is down 38 percent, having been halted numerous times.
UPDATE: It is now being said among biotech watchers that Pfizer noted "problems" lingering with FDA on the re-file.
From @adamfeuerstein on twitter:
RT @JNapodano: @adamfeuerstein Yes, apparently $PFE noted "problems" lingering with FDA on the re-file.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regenxbio shares jump after FDA agrees to reverse drug rejection
- FDA approves Merck's Capvaxive for children at higher pneumonia risk
- FDA backs Entera Bio's Phase 3 trial plan for oral osteoporosis drug
Create E-mail Alert Related Categories
FDA, Trader TalkRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
